Katie Tryhane
Stock Analyst at Credit Suisse
(1.97)
# 2,987
Out of 4,876 analysts
21
Total ratings
50%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Katie Tryhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Initiates: Outperform | $285 | $150.01 | +89.99% | 1 | Aug 25, 2022 | |
| AVTR Avantor | Maintains: Outperform | $47 → $50 | $13.53 | +269.55% | 1 | Sep 10, 2021 | |
| DHR Danaher | Maintains: Outperform | $306 → $370 | $198.80 | +86.12% | 1 | Sep 10, 2021 | |
| SOPH SOPHiA GENETICS | Initiates: Outperform | $22 | $3.10 | +609.68% | 1 | Aug 17, 2021 | |
| IDXX IDEXX Laboratories | Maintains: Outperform | $735 → $770 | $531.32 | +44.92% | 2 | Aug 13, 2021 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Outperform | $44 → $54 | $2.47 | +2,086.23% | 3 | Aug 11, 2021 | |
| FLGT Fulgent Genetics | Maintains: Underperform | $55 → $65 | $19.68 | +230.28% | 2 | Aug 10, 2021 | |
| ZTS Zoetis | Maintains: Outperform | $206 → $230 | $156.17 | +47.28% | 2 | Aug 9, 2021 | |
| NVST Envista Holdings | Maintains: Outperform | $49 → $55 | $19.67 | +179.61% | 2 | May 6, 2021 | |
| LNTH Lantheus Holdings | Maintains: Neutral | $17 → $20 | $81.49 | -75.46% | 1 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $488 → $490 | $408.28 | +20.02% | 2 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $432 → $515 | $188.52 | +173.18% | 2 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $235 | $144.56 | +62.56% | 1 | Oct 22, 2020 |
Charles River Laboratories International
Aug 25, 2022
Initiates: Outperform
Price Target: $285
Current: $150.01
Upside: +89.99%
Avantor
Sep 10, 2021
Maintains: Outperform
Price Target: $47 → $50
Current: $13.53
Upside: +269.55%
Danaher
Sep 10, 2021
Maintains: Outperform
Price Target: $306 → $370
Current: $198.80
Upside: +86.12%
SOPHiA GENETICS
Aug 17, 2021
Initiates: Outperform
Price Target: $22
Current: $3.10
Upside: +609.68%
IDEXX Laboratories
Aug 13, 2021
Maintains: Outperform
Price Target: $735 → $770
Current: $531.32
Upside: +44.92%
Maravai LifeSciences Holdings
Aug 11, 2021
Maintains: Outperform
Price Target: $44 → $54
Current: $2.47
Upside: +2,086.23%
Fulgent Genetics
Aug 10, 2021
Maintains: Underperform
Price Target: $55 → $65
Current: $19.68
Upside: +230.28%
Zoetis
Aug 9, 2021
Maintains: Outperform
Price Target: $206 → $230
Current: $156.17
Upside: +47.28%
Envista Holdings
May 6, 2021
Maintains: Outperform
Price Target: $49 → $55
Current: $19.67
Upside: +179.61%
Lantheus Holdings
May 5, 2021
Maintains: Neutral
Price Target: $17 → $20
Current: $81.49
Upside: -75.46%
Dec 2, 2020
Maintains: Neutral
Price Target: $488 → $490
Current: $408.28
Upside: +20.02%
Nov 24, 2020
Maintains: Outperform
Price Target: $432 → $515
Current: $188.52
Upside: +173.18%
Oct 22, 2020
Maintains: Outperform
Price Target: $230 → $235
Current: $144.56
Upside: +62.56%